Detalhe da pesquisa
1.
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Blood
; 137(25): 3473-3483, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33754642
2.
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Am J Hematol
; 95(12): 1457-1465, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32777116
3.
Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding.
J Immunol
; 198(6): 2500-2512, 2017 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28159900
4.
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Blood
; 135(24): 2192-2195, 2020 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32232486
5.
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status.
PLoS Genet
; 9(3): e1003311, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23505378
6.
Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas.
Blood
; 121(2): 351-9, 2013 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23160471
7.
TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.
Br J Haematol
; 183(3): 509-512, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048125
8.
Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts.
NAR Genom Bioinform
; 2(4): lqaa070, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33043294
9.
Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia.
Oncotarget
; 9(4): 4354-4365, 2018 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435107
10.
Retraction Notice to: miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation.
Cancer Cell
; 40(11): 1440, 2022 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36306794
11.
Retraction Note: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Nat Med
; 28(11): 2436, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195688
12.
Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias.
Oncotarget
; 7(34): 54174-54182, 2016 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27527866
13.
A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells.
Oncotarget
; 7(21): 29927-36, 2016 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-27166255
14.
Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD).
Int J Bone Marrow Res
; 2: 079-82, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-34079960
15.
Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel.
PLoS One
; 8(11): e78610, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24223161
16.
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Nat Med
; 18(1): 74-82, 2011 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-22157681
17.
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.
J Natl Cancer Inst
; 102(10): 706-21, 2010 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-20388878
18.
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.
Cancer Cell
; 16(6): 498-509, 2009 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-19962668
19.
Human cytomegalovirus DNA polymerase catalytic subunit pUL54 possesses independently acting nuclear localization and ppUL44 binding motifs.
Traffic
; 7(10): 1322-32, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16911590